lactic acid has been researched along with Arteriosclerosis, Coronary in 45 studies
Lactic Acid: A normal intermediate in the fermentation (oxidation, metabolism) of sugar. The concentrated form is used internally to prevent gastrointestinal fermentation. (From Stedman, 26th ed)
2-hydroxypropanoic acid : A 2-hydroxy monocarboxylic acid that is propanoic acid in which one of the alpha-hydrogens is replaced by a hydroxy group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We sought to assess the effects of heparin and the potential protective effects of trimetazidine (TMZ) on exercise performance, plasma nitric oxide (NO), endothelin-1 (ET-1) and free fatty acid (FFA) release in patients with stable coronary artery disease (CAD)." | 9.10 | Acute effects of heparin administration on the ischemic threshold of patients with coronary artery disease: evaluation of the protective role of the metabolic modulator trimetazidine. ( Calori, G; Chierchia, S; Fragasso, G; Lu, C; Margonato, A; Monti, L; Palloshi, A; Piatti, PM; Pozza, G; Setola, E; Valsecchi, G, 2002) |
| "Treatment with rosiglitazone, a peroxisome proliferator-activated receptor-γ agonist, in type 2 diabetic mellitus (T2DM) patients is under scrutiny because it affects adversely cardiovascular outcomes." | 6.79 | Systemic metabolic markers and myocardial glucose uptake in type 2 diabetic and coronary artery disease patients treated for 16 weeks with rosiglitazone, a PPARγ agonist. ( Ala-Korpela, M; Badeau, RM; Honka, MJ; Kangas, AJ; Lautamäki, R; Nuutila, P; Soininen, P; Stewart, M, 2014) |
| " The DESolve system, designed to provide vessel support and neointimal suppression, combines a poly-l-lactic acid-based scaffold with the antiproliferative myolimus." | 5.19 | A next-generation bioresorbable coronary scaffold system: from bench to first clinical evaluation: 6- and 12-month clinical and multimodality imaging results. ( Abizaid, A; Abizaid, AS; Bhat, V; Chamie, D; Costa, JR; Costa, R; Morrison, L; Ormiston, JA; Pinto, I; Sanidas, E; Stewart, J; Toyloy, S; Verheye, S; Webster, M; Yan, J, 2014) |
| "We sought to assess the effects of heparin and the potential protective effects of trimetazidine (TMZ) on exercise performance, plasma nitric oxide (NO), endothelin-1 (ET-1) and free fatty acid (FFA) release in patients with stable coronary artery disease (CAD)." | 5.10 | Acute effects of heparin administration on the ischemic threshold of patients with coronary artery disease: evaluation of the protective role of the metabolic modulator trimetazidine. ( Calori, G; Chierchia, S; Fragasso, G; Lu, C; Margonato, A; Monti, L; Palloshi, A; Piatti, PM; Pozza, G; Setola, E; Valsecchi, G, 2002) |
| "Treatment with rosiglitazone, a peroxisome proliferator-activated receptor-γ agonist, in type 2 diabetic mellitus (T2DM) patients is under scrutiny because it affects adversely cardiovascular outcomes." | 2.79 | Systemic metabolic markers and myocardial glucose uptake in type 2 diabetic and coronary artery disease patients treated for 16 weeks with rosiglitazone, a PPARγ agonist. ( Ala-Korpela, M; Badeau, RM; Honka, MJ; Kangas, AJ; Lautamäki, R; Nuutila, P; Soininen, P; Stewart, M, 2014) |
| " Multivariate analysis showed that statin dosage was independently associated with MD (OR:1." | 1.36 | Mitochondrial dysfunction induced by statin contributes to endothelial dysfunction in patients with coronary artery disease. ( Chan, HT; Dai, YL; Fong, B; Lau, CP; Lee, SW; Li, SW; Luk, TH; Siu, CW; Tam, S; Tse, HF; Yiu, KH, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (4.44) | 18.2507 |
| 2000's | 17 (37.78) | 29.6817 |
| 2010's | 23 (51.11) | 24.3611 |
| 2020's | 3 (6.67) | 2.80 |
| Authors | Studies |
|---|---|
| Gibson, ME | 1 |
| Gray, K | 1 |
| Hendrix, RHJ | 1 |
| Ganushchak, YM | 1 |
| Weerwind, PW | 1 |
| Couselo-Seijas, M | 1 |
| Agra-Bermejo, RM | 1 |
| Fernández, AL | 1 |
| Martínez-Cereijo, JM | 1 |
| Sierra, J | 1 |
| Soto-Pérez, M | 1 |
| Rozados-Luis, A | 1 |
| González-Juanatey, JR | 1 |
| Eiras, S | 1 |
| Cure, E | 1 |
| Cumhur Cure, M | 1 |
| Zhu, Y | 1 |
| Ji, JJ | 1 |
| Wang, XD | 1 |
| Sun, XJ | 1 |
| Li, M | 1 |
| Wei, Q | 1 |
| Ren, LQ | 1 |
| Liu, NF | 1 |
| Naghipoor, J | 1 |
| Rabczuk, T | 1 |
| Verheye, S | 1 |
| Ormiston, JA | 3 |
| Stewart, J | 1 |
| Webster, M | 1 |
| Sanidas, E | 1 |
| Costa, R | 1 |
| Costa, JR | 1 |
| Chamie, D | 1 |
| Abizaid, AS | 1 |
| Pinto, I | 1 |
| Morrison, L | 1 |
| Toyloy, S | 1 |
| Bhat, V | 1 |
| Yan, J | 1 |
| Abizaid, A | 1 |
| Badeau, RM | 1 |
| Honka, MJ | 1 |
| Lautamäki, R | 1 |
| Stewart, M | 1 |
| Kangas, AJ | 1 |
| Soininen, P | 1 |
| Ala-Korpela, M | 1 |
| Nuutila, P | 1 |
| Zhao, J | 1 |
| Cheng, Z | 1 |
| Quan, X | 1 |
| Zhao, Z | 1 |
| Lü, F | 1 |
| Liu, X | 1 |
| Nishio, S | 2 |
| Takeda, S | 2 |
| Kosuga, K | 2 |
| Okada, M | 2 |
| Kyo, E | 2 |
| Tsuji, T | 2 |
| Takeuchi, E | 2 |
| Terashima, T | 1 |
| Inuzuka, Y | 2 |
| Hata, T | 2 |
| Takeuchi, Y | 2 |
| Harita, T | 2 |
| Seki, J | 2 |
| Ikeguchi, S | 2 |
| Mattesini, A | 2 |
| Pighi, M | 1 |
| Konstantinidis, N | 1 |
| Ghione, M | 2 |
| Kilic, D | 1 |
| Foin, N | 2 |
| Dall'ara, G | 2 |
| Secco, GG | 2 |
| Valente, S | 2 |
| Di Mario, C | 2 |
| Lan, Z | 1 |
| Lyu, Y | 1 |
| Xiao, J | 1 |
| Zheng, X | 1 |
| He, S | 1 |
| Feng, G | 1 |
| Zhang, Y | 1 |
| Wang, S | 2 |
| Kislauskis, E | 1 |
| Chen, J | 1 |
| McCarthy, S | 2 |
| Laham, R | 2 |
| Jiang, X | 1 |
| Wu, T | 2 |
| Wang, Y | 1 |
| Dong, P | 1 |
| Li, L | 1 |
| Li, X | 1 |
| Wang, H | 1 |
| Yang, X | 1 |
| Li, Z | 1 |
| Shang, X | 1 |
| Rama-Merchan, JC | 1 |
| Lupi, A | 1 |
| Viceconte, N | 1 |
| Lindsay, AC | 1 |
| De Silva, R | 1 |
| Naganuma, T | 1 |
| Colombo, A | 1 |
| Wiebe, J | 1 |
| Nef, HM | 1 |
| Hamm, CW | 1 |
| Reiss, S | 1 |
| Krafft, AJ | 1 |
| Zehender, M | 1 |
| Heidt, T | 1 |
| Pfannebecker, T | 1 |
| Bode, C | 1 |
| Bock, M | 1 |
| von Zur Muhlen, C | 1 |
| Akasaka, T | 1 |
| Hokimoto, S | 1 |
| Sueta, D | 1 |
| Tabata, N | 1 |
| Sakamoto, K | 1 |
| Yamamoto, E | 1 |
| Yamamuro, M | 1 |
| Tsujita, K | 1 |
| Kojima, S | 1 |
| Kaikita, K | 1 |
| Kajiwara, A | 1 |
| Morita, K | 1 |
| Oniki, K | 1 |
| Saruwatari, J | 1 |
| Nakagawa, K | 1 |
| Ogata, Y | 1 |
| Ogawa, H | 1 |
| Caruso, FR | 1 |
| Bonjorno, JC | 1 |
| Arena, R | 1 |
| Phillips, SA | 1 |
| Cabiddu, R | 1 |
| Mendes, RG | 1 |
| Arakelian, VM | 1 |
| Bassi, D | 1 |
| Borghi-Silva, A | 1 |
| Vesga, B | 1 |
| Hernandez, H | 1 |
| Moncada, M | 1 |
| Gasior, P | 1 |
| Higuera, S | 1 |
| Dager, A | 1 |
| Arana, C | 1 |
| Delgado, JA | 1 |
| Généreux, P | 1 |
| Maehara, A | 1 |
| Granada, JF | 1 |
| Tanimoto, S | 3 |
| Bruining, N | 4 |
| van Domburg, RT | 3 |
| Rotger, D | 1 |
| Radeva, P | 1 |
| Ligthart, JM | 1 |
| Serruys, PW | 6 |
| Otsuka, M | 1 |
| Weustink, A | 1 |
| Ligthart, J | 1 |
| de Winter, S | 3 |
| van Mieghem, C | 1 |
| Nieman, K | 1 |
| de Feyter, PJ | 1 |
| Grube, E | 2 |
| Sievert, H | 1 |
| Hauptmann, KE | 1 |
| Mueller, R | 1 |
| Gerckens, U | 1 |
| Buellesfeld, L | 2 |
| Ako, J | 1 |
| Shimohama, T | 1 |
| Costa, M | 1 |
| Fitzgerald, P | 1 |
| Turer, AT | 1 |
| Stevens, RD | 1 |
| Bain, JR | 1 |
| Muehlbauer, MJ | 1 |
| van der Westhuizen, J | 1 |
| Mathew, JP | 1 |
| Schwinn, DA | 1 |
| Glower, DD | 1 |
| Newgard, CB | 1 |
| Podgoreanu, MV | 1 |
| Kratnov, AE | 1 |
| Khabarova, IV | 1 |
| Kratnov, AA | 1 |
| Dai, YL | 2 |
| Luk, TH | 2 |
| Siu, CW | 2 |
| Yiu, KH | 2 |
| Chan, HT | 1 |
| Lee, SW | 1 |
| Li, SW | 2 |
| Tam, S | 2 |
| Fong, B | 2 |
| Lau, CP | 1 |
| Tse, HF | 2 |
| Roelandt, JR | 1 |
| Regar, E | 2 |
| Heller, I | 1 |
| Hamers, R | 1 |
| Onuma, Y | 3 |
| Dudek, D | 3 |
| Webster, MW | 1 |
| Thuesen, L | 3 |
| Cheong, WF | 1 |
| Miquel-Hebert, K | 1 |
| Veldhof, S | 1 |
| Ma, X | 1 |
| Oyamada, S | 1 |
| Gao, F | 1 |
| Robich, MP | 1 |
| Wu, H | 1 |
| Wang, X | 1 |
| Buchholz, B | 1 |
| Gu, Z | 1 |
| Bianchi, CF | 1 |
| Sellke, FW | 1 |
| Igaki, K | 1 |
| Kawada, Y | 1 |
| Akamatsu, S | 1 |
| Hasegawa, S | 1 |
| Brugaletta, S | 2 |
| Muramatsu, T | 1 |
| Waksman, R | 1 |
| Gutiérrez-Chico, JL | 1 |
| Gijsen, F | 1 |
| Wentzel, J | 1 |
| de Bruyne, B | 2 |
| Ormiston, J | 1 |
| McClean, DR | 1 |
| Windecker, S | 1 |
| Chevalier, B | 2 |
| Whitbourn, R | 1 |
| Wong, WK | 1 |
| Immke, DC | 1 |
| McCleskey, EW | 1 |
| Meyer, K | 1 |
| Steiner, R | 1 |
| Lastayo, P | 1 |
| Lippuner, K | 1 |
| Allemann, Y | 1 |
| Eberli, F | 1 |
| Schmid, J | 1 |
| Saner, H | 1 |
| Hoppeler, H | 1 |
| Koskenkari, JK | 1 |
| Kaukoranta, PK | 1 |
| Kiviluoma, KT | 1 |
| Raatikainen, MJ | 1 |
| Ohtonen, PP | 1 |
| Ala-Kokko, TI | 1 |
| Bitzikas, G | 1 |
| Papakonstantinou, C | 1 |
| Lazou, A | 1 |
| Bougioukas, G | 1 |
| Toumpouras, M | 1 |
| Tripsianis, G | 1 |
| Spanos, P | 1 |
| Mierdl, S | 1 |
| Meininger, D | 1 |
| Dogan, S | 1 |
| Wimmer-Greinecker, G | 1 |
| Westphal, K | 1 |
| Bremerich, DH | 1 |
| Byhahn, C | 1 |
| Hudorovic, N | 1 |
| Lemos, PA | 1 |
| Sharkawi, T | 1 |
| Cornhill, F | 1 |
| Lafont, A | 1 |
| Sabaria, P | 1 |
| Vert, M | 1 |
| Häggmark, S | 1 |
| Haney, MF | 1 |
| Johansson, G | 1 |
| Reiz, S | 1 |
| Näslund, U | 1 |
| Augustinsson, LE | 1 |
| Eliasson, T | 1 |
| Mannheimer, C | 1 |
| Mohri, M | 1 |
| Koyanagi, M | 1 |
| Egashira, K | 1 |
| Tagawa, H | 1 |
| Ichiki, T | 1 |
| Shimokawa, H | 1 |
| Takeshita, A | 1 |
| Fragasso, G | 1 |
| Piatti, PM | 1 |
| Monti, L | 1 |
| Palloshi, A | 1 |
| Lu, C | 1 |
| Valsecchi, G | 1 |
| Setola, E | 1 |
| Calori, G | 1 |
| Pozza, G | 1 |
| Margonato, A | 1 |
| Chierchia, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Percutaneous Coronary Intervention With the ANgiolite Drug-Eluting Stent: an Optical CoHerence TOmogRaphy Study. The ANCHOR Study[NCT02776267] | 100 participants (Anticipated) | Interventional | 2015-05-31 | Completed | |||
| Bioabsorbable Drug-eluting Scaffolds (BVS)-Optical Coherence Tomography (OCT) Imaging Study[NCT03194711] | 40 participants (Actual) | Observational | 2017-05-30 | Completed | |||
| Bioabsorbable Vascular Solutions First in Man Clinical Investigation: A Clinical Evaluation of the Bioabsorbable Vascular Solutions Everolimus Eluting Coronary Stent System (BVS EECSS) in the Treatment of Patients With Single de Novo Native Coronary Arter[NCT00300131] | 30 participants (Actual) | Observational | 2006-03-31 | Completed | |||
| A Clinical Evaluation of the Bioabsorbable Everolimus Eluting Coronary Stent System (BVS EECSS) in the Treatment of Patients With de Novo Native Coronary Artery Lesions.[NCT00856856] | 101 participants (Actual) | Interventional | 2009-03-31 | Completed | |||
| A Randomized Optical Coherence Tomography Study Comparing Resolute Integrity to Biomatrix Drug-eluting Stent on the Degree of Early Stent Healing and Late Lumen Loss.The OCT-ORION Study[NCT01742507] | Phase 4 | 60 participants (Actual) | Interventional | 2012-04-30 | Completed | ||
| A Randomised Controlled Trial of the Effect of Remote Ischaemic Conditioning on Coronary Endothelial Function in Patients With Angina.[NCT02666235] | Phase 2 | 60 participants (Actual) | Interventional | 2011-07-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT00856856)
Timeframe: 2 years
| Intervention | Percent of Covered Struts (Mean) |
|---|---|
| Absorb BVS | 98.07 |
(NCT00856856)
Timeframe: 3 years
| Intervention | Percent of Covered Struts (Mean) |
|---|---|
| Absorb BVS | 97.90 |
(NCT00856856)
Timeframe: 1 year
| Intervention | Percent of Covered Struts (Mean) |
|---|---|
| Absorb BVS | 96.86 |
(NCT00856856)
Timeframe: 1 year
| Intervention | Percent of Uncovered Struts (Mean) |
|---|---|
| Absorb BVS | 3.14 |
(NCT00856856)
Timeframe: 2 years
| Intervention | Percent of Uncovered Struts (Mean) |
|---|---|
| Absorb BVS | 1.93 |
(NCT00856856)
Timeframe: 3 years
| Intervention | Percent of Uncovered Struts (Mean) |
|---|---|
| Absorb BVS | 2.10 |
An abnormal expansion or protrusion of a coronary blood vessel resulting from a disease or weakening of the vessel's wall (all three layers) that exceeds the RVD of the vessel by 1.5 times. (NCT00856856)
Timeframe: 1 year
| Intervention | Percentage of participants (Number) |
|---|---|
| Absorb BVS | 0.0 |
An abnormal expansion or protrusion of a coronary blood vessel resulting from a disease or weakening of the vessel's wall (all three layers) that exceeds the RVD of the vessel by 1.5 times. (NCT00856856)
Timeframe: 180 days
| Intervention | Percentage of participants (Number) |
|---|---|
| Absorb BVS | 2.4 |
An abnormal expansion or protrusion of a coronary blood vessel resulting from a disease or weakening of the vessel's wall (all three layers) that exceeds the RVD of the vessel by 1.5 times. (NCT00856856)
Timeframe: 2 years
| Intervention | Percentage of participants (Number) |
|---|---|
| Absorb BVS | 2.6 |
An abnormal expansion or protrusion of a coronary blood vessel resulting from a disease or weakening of the vessel's wall (all three layers) that exceeds the RVD of the vessel by 1.5 times. (NCT00856856)
Timeframe: 3 years
| Intervention | Percentage of participants (Number) |
|---|---|
| Absorb BVS | 2.08 |
An abnormal expansion or protrusion of a coronary blood vessel resulting from a disease or weakening of the vessel's wall (all three layers) that exceeds the RVD of the vessel by 1.5 times. (NCT00856856)
Timeframe: 5 years
| Intervention | Percentage of participants (Number) |
|---|---|
| Absorb BVS | 0.0 |
"Cardiac death is defined as any death in which a cardiac cause cannot be excluded.~(This includes but is not limited to acute myocardial infarction, cardiac perforation/pericardial tamponade, arrhythmia or conduction abnormality, cerebrovascular accident within 30 days of the procedure or cerebrovascular accident suspected of being related to the procedure, death due to complication of the procedure, including bleeding, vascular repair, transfusion reaction, or bypass surgery.)" (NCT00856856)
Timeframe: 1 year
| Intervention | percentage of participants (Number) |
|---|---|
| ABSORB Stent | 0 |
"Cardiac death is defined as any death in which a cardiac cause cannot be excluded.~(This includes but is not limited to acute myocardial infarction, cardiac perforation/pericardial tamponade, arrhythmia or conduction abnormality, cerebrovascular accident within 30 days of the procedure or cerebrovascular accident suspected of being related to the procedure, death due to complication of the procedure, including bleeding, vascular repair, transfusion reaction, or bypass surgery.)" (NCT00856856)
Timeframe: 2 years
| Intervention | percentage of participants (Number) |
|---|---|
| ABSORB Stent | 0 |
"Cardiac death is defined as any death in which a cardiac cause cannot be excluded.~(This includes but is not limited to acute myocardial infarction, cardiac perforation/pericardial tamponade, arrhythmia or conduction abnormality, cerebrovascular accident within 30 days of the procedure or cerebrovascular accident suspected of being related to the procedure, death due to complication of the procedure, including bleeding, vascular repair, transfusion reaction, or bypass surgery.)" (NCT00856856)
Timeframe: 3 years
| Intervention | percentage of participants (Number) |
|---|---|
| ABSORB Stent | 0 |
"Cardiac death is defined as any death in which a cardiac cause cannot be excluded.~(This includes but is not limited to acute myocardial infarction, cardiac perforation/pericardial tamponade, arrhythmia or conduction abnormality, cerebrovascular accident within 30 days of the procedure or cerebrovascular accident suspected of being related to the procedure, death due to complication of the procedure, including bleeding, vascular repair, transfusion reaction, or bypass surgery.)" (NCT00856856)
Timeframe: 30 days
| Intervention | percentage of participants (Number) |
|---|---|
| ABSORB Stent | 0 |
"Cardiac death is defined as any death in which a cardiac cause cannot be excluded.~(This includes but is not limited to acute myocardial infarction, cardiac perforation/pericardial tamponade, arrhythmia or conduction abnormality, cerebrovascular accident within 30 days of the procedure or cerebrovascular accident suspected of being related to the procedure, death due to complication of the procedure, including bleeding, vascular repair, transfusion reaction, or bypass surgery.)" (NCT00856856)
Timeframe: 4 years
| Intervention | percentage of participants (Number) |
|---|---|
| ABSORB Stent | 0 |
"Cardiac death is defined as any death in which a cardiac cause cannot be excluded.~(This includes but is not limited to acute myocardial infarction, cardiac perforation/pericardial tamponade, arrhythmia or conduction abnormality, cerebrovascular accident within 30 days of the procedure or cerebrovascular accident suspected of being related to the procedure, death due to complication of the procedure, including bleeding, vascular repair, transfusion reaction, or bypass surgery.)" (NCT00856856)
Timeframe: 5 years
| Intervention | percentage of participants (Number) |
|---|---|
| ABSORB Stent | 0 |
Successful delivery and deployment of the Clinical Investigation scaffold at the intended target lesion and successful withdrawal of the scaffold delivery system with attainment of final residual stenosis of less than 50% of the target lesion by QCA (by visual estimation if QCA unavailable). Standard pre-dilation catheters and post-dilatation catheters (if applicable) may be used. Bailout patients will be included as device success only if the above criteria for clinical device are met. (NCT00856856)
Timeframe: On day 0 (the day of procedure)
| Intervention | percentage of lesions (Number) |
|---|---|
| Absorb BVS | 100.0 |
Successful delivery and deployment of the Clinical Investigation scaffold at the intended target lesion and successful withdrawal of the scaffold delivery system with attainment of final residual stenosis of less than 50% of the target lesion by QCA (by visual estimation if QCA unavailable) and/or using any adjunctive device without the occurrence of ischemia-driven major adverse cardiac event (MACE) during the hospital stay with a maximum of first seven days post index procedure. (NCT00856856)
Timeframe: On day 0 (the day of procedure)
| Intervention | percentage of participants (Number) |
|---|---|
| ABSORB Stent | 98.0 |
Distal Late Loss: distal MLD post-procedure - distal MLD at follow-up (distal defined as within 5 mm of healthy tissue distal to scaffold placement). (NCT00856856)
Timeframe: 1 year
| Intervention | Millimeter (Mean) |
|---|---|
| Absorb BVS | 0.07 |
Distal Late Loss: distal MLD post-procedure - distal MLD at follow-up (distal defined as within 5 mm of healthy tissue distal to scaffold placement). (NCT00856856)
Timeframe: 180 days
| Intervention | Millimeter (Mean) |
|---|---|
| Absorb BVS | 0.07 |
Distal Late Loss: distal MLD post-procedure - distal MLD at follow-up (distal defined as within 5 mm of healthy tissue distal to scaffold placement). (NCT00856856)
Timeframe: 2 years
| Intervention | Millimeter (Mean) |
|---|---|
| Absorb BVS | 0.04 |
Distal Late Loss: distal MLD post-procedure - distal MLD at follow-up (distal defined as within 5 mm of healthy tissue distal to scaffold placement). (NCT00856856)
Timeframe: 3 years
| Intervention | Millimeter (Mean) |
|---|---|
| Absorb BVS | 0.08 |
Distal Late Loss: distal MLD post-procedure - distal MLD at follow-up (distal defined as within 5 mm of healthy tissue distal to scaffold placement). (NCT00856856)
Timeframe: 5 years
| Intervention | Millimeter (Mean) |
|---|---|
| Absorb BVS | 0.11 |
Major adverse cardiac events (MACE) is defined as the composite of cardiac death, all myocardial infarction,and clinically indicated target lesion revascularization (CI-TLR). (NCT00856856)
Timeframe: 1 year
| Intervention | percentage of participants (Number) |
|---|---|
| Absorb BVS | 6.9 |
Major adverse cardiac events (MACE) is defined as the composite of cardiac death, all myocardial infarction,and clinically indicated target lesion revascularization (CI-TLR). (NCT00856856)
Timeframe: 180 days
| Intervention | percentage of participants (Number) |
|---|---|
| Absorb BVS | 5.0 |
Major adverse cardiac events (MACE) is defined as the composite of cardiac death, all myocardial infarction,and clinically indicated target lesion revascularization (CI-TLR). (NCT00856856)
Timeframe: 2 years
| Intervention | percentage of participants (Number) |
|---|---|
| Absorb BVS | 9.0 |
Major adverse cardiac events (MACE) is defined as the composite of cardiac death, all myocardial infarction,and clinically indicated target lesion revascularization (CI-TLR). (NCT00856856)
Timeframe: 270 days
| Intervention | percentage of participants (Number) |
|---|---|
| Absorb BVS | 5.0 |
Major adverse cardiac events (MACE) is defined as the composite of cardiac death, all myocardial infarction,and clinically indicated target lesion revascularization (CI-TLR). (NCT00856856)
Timeframe: 3 years
| Intervention | percentage of participants (Number) |
|---|---|
| Absorb BVS | 10.0 |
Major adverse cardiac events (MACE) is defined as the composite of cardiac death, all myocardial infarction,and clinically indicated target lesion revascularization (CI-TLR). (NCT00856856)
Timeframe: 30 days
| Intervention | percentage of participants (Number) |
|---|---|
| Absorb BVS | 2.0 |
Major adverse cardiac events (MACE) is defined as the composite of cardiac death, all myocardial infarction,and clinically indicated target lesion revascularization (CI-TLR). (NCT00856856)
Timeframe: 4 years
| Intervention | percentage of participants (Number) |
|---|---|
| Absorb BVS | 10.1 |
Major adverse cardiac events (MACE) is defined as the composite of cardiac death, all myocardial infarction,and clinically indicated target lesion revascularization (CI-TLR). (NCT00856856)
Timeframe: 5 years
| Intervention | percentage of participants (Number) |
|---|---|
| Absorb BVS | 11.0 |
Target Vessel Failure (TVF) is the composite of Cardiac Death, Myocardial infarction (MI) or Ischemic-Driven Target Vessel Revascularization (ID-TVR). (NCT00856856)
Timeframe: 1 year
| Intervention | percentage of participants (Number) |
|---|---|
| Absorb BVS | 6.9 |
Target Vessel Failure (TVF) is the composite of Cardiac Death, Myocardial infarction (MI) or Ischemic-Driven Target Vessel Revascularization (ID-TVR). (NCT00856856)
Timeframe: 180 days
| Intervention | Percentage of participants (Number) |
|---|---|
| ABSORB Stent | 5.0 |
Target Vessel Failure (TVF) is the composite of Cardiac Death, Myocardial infarction (MI) or Ischemic-Driven Target Vessel Revascularization (ID-TVR). (NCT00856856)
Timeframe: 2 years
| Intervention | percentage of participants (Number) |
|---|---|
| Absorb BVS | 11.0 |
Target Vessel Failure (TVF) is the composite of Cardiac Death, Myocardial infarction (MI) or Ischemic-Driven Target Vessel Revascularization (ID-TVR). (NCT00856856)
Timeframe: 270 days
| Intervention | Percentage of participants (Number) |
|---|---|
| Absorb Stent | 5.0 |
Target Vessel Failure (TVF) is the composite of Cardiac Death, Myocardial infarction (MI) or Ischemic-Driven Target Vessel Revascularization (ID-TVR). (NCT00856856)
Timeframe: 3 years
| Intervention | percentage of participants (Number) |
|---|---|
| Absorb BVS | 13.0 |
Target Vessel Failure (TVF) is the composite of Cardiac Death, Myocardial infarction (MI) or Ischemic-Driven Target Vessel Revascularization (ID-TVR). (NCT00856856)
Timeframe: 30 days
| Intervention | percentage of participants (Number) |
|---|---|
| Absorb BVS | 2.0 |
Target Vessel Failure (TVF) is the composite of Cardiac Death, Myocardial infarction (MI) or Ischemic-Driven Target Vessel Revascularization (ID-TVR). (NCT00856856)
Timeframe: 4 years
| Intervention | percentage of participants (Number) |
|---|---|
| Absorb BVS | 13.1 |
Target Vessel Failure (TVF) is the composite of Cardiac Death, Myocardial infarction (MI) or Ischemic-Driven Target Vessel Revascularization (ID-TVR). (NCT00856856)
Timeframe: 5 years
| Intervention | percentage of participants (Number) |
|---|---|
| Absorb BVS | 14.0 |
Percent of patients with a followup percent diameter stenosis of >=50% per QCA. (NCT00856856)
Timeframe: 1 year
| Intervention | Percentage of participants (Number) |
|---|---|
| Absorb BVS | 3.5 |
Percent of patients with a followup percent diameter stenosis of >=50% per QCA. (NCT00856856)
Timeframe: 180 days
| Intervention | Percentage of participants (Number) |
|---|---|
| Absorb BVS | 0.0 |
Percent of patients with a followup percent diameter stenosis of >=50% per QCA. (NCT00856856)
Timeframe: 2 years
| Intervention | Percentage of participants (Number) |
|---|---|
| Absorb BVS | 0.0 |
Percent of patients with a followup percent diameter stenosis of >=50% per QCA. (NCT00856856)
Timeframe: 3 years
| Intervention | Percentage of participants (Number) |
|---|---|
| Absorb BVS | 7.8 |
Percent of patients with a followup percent diameter stenosis of >=50% per QCA. (NCT00856856)
Timeframe: 5 years
| Intervention | Percentage of participants (Number) |
|---|---|
| Absorb BVS | 7.8 |
In-scaffold Late Loss: in-scaffold MLD post-procedure - in-scaffold MLD at follow-up. (NCT00856856)
Timeframe: 2 years
| Intervention | Millimeter (Mean) |
|---|---|
| Absorb BVS | 0.27 |
In-scaffold Late Loss: in-scaffold MLD post-procedure - in-scaffold MLD at follow-up. (NCT00856856)
Timeframe: 3 years
| Intervention | Millimeter (Mean) |
|---|---|
| Absorb BVS | 0.29 |
In-scaffold Late Loss: in-scaffold MLD post-procedure - in-scaffold MLD at follow-up. (NCT00856856)
Timeframe: 5 years
| Intervention | Millimeter (Mean) |
|---|---|
| Absorb BVS | 0.26 |
In-scaffold Late Loss: in-scaffold MLD post-procedure - in-scaffold MLD at follow-up (NCT00856856)
Timeframe: 1 year
| Intervention | Millimeter (Mean) |
|---|---|
| Absorb BVS | 0.27 |
In-scaffold Late Loss: in-scaffold MLD post-procedure - in-scaffold MLD at follow-up. (NCT00856856)
Timeframe: 180 days
| Intervention | Millimeter (Mean) |
|---|---|
| Absorb BVS | 0.19 |
Percent Diameter Stenosis is defined as the value calculated as 100 * (1 - MLD/RVD) using the mean values from two orthogonal views (when possible) by QCA. (NCT00856856)
Timeframe: 1 year
| Intervention | percentage of diameter stenosis (Mean) |
|---|---|
| Absorb BVS | 21.35 |
Percent Diameter Stenosis is defined as the value calculated as 100 * (1 - MLD/RVD) using the mean values from two orthogonal views (when possible) by QCA. (NCT00856856)
Timeframe: 180 days
| Intervention | percentage of diameter stenosis (Mean) |
|---|---|
| Absorb BVS | 19.21 |
Percent Diameter Stenosis is defined as the value calculated as 100 * (1 - MLD/RVD) using the mean values from two orthogonal views (when possible) by QCA. (NCT00856856)
Timeframe: 2 years
| Intervention | percentage of diameter stenosis (Mean) |
|---|---|
| Absorb BVS | 20.94 |
Percent Diameter Stenosis is defined as the value calculated as 100 * (1 - MLD/RVD) using the mean values from two orthogonal views (when possible) by QCA. (NCT00856856)
Timeframe: 3 years
| Intervention | percentage of diameter stenosis (Mean) |
|---|---|
| Absorb BVS | 23.16 |
Percent Diameter Stenosis is defined as the value calculated as 100 * (1 - MLD/RVD) using the mean values from two orthogonal views (when possible) by QCA. (NCT00856856)
Timeframe: 5 years
| Intervention | percentage of diameter stenosis (Mean) |
|---|---|
| Absorb BVS | 22.74 |
"ID-TLR is defined as the revascularization at the target lesion associated with any of the following:~Positive functional ischemia study~Ischemic symptoms and angiographic minimal lumen diameter stenosis ≥ 50% by core laboratory quantitative coronary angiography (QCA)~Revascularization of a target lesion with diameter stenosis ≥ 70% by core laboratory QCA without either ischemic symptoms or a positive functional study." (NCT00856856)
Timeframe: 1 year
| Intervention | percentage of participants (Number) |
|---|---|
| Absorb BVS | 4.0 |
"ID-TLR is defined as the revascularization at the target lesion associated with any of the following:~Positive functional ischemia study~Ischemic symptoms and angiographic minimal lumen diameter stenosis ≥ 50% by core laboratory quantitative coronary angiography (QCA)~Revascularization of a target lesion with diameter stenosis ≥ 70% by core laboratory QCA without either ischemic symptoms or a positive functional study." (NCT00856856)
Timeframe: 180 days
| Intervention | Percentage of participants (Number) |
|---|---|
| Absorb BVS | 2.0 |
"ID-TLR is defined as the revascularization at the target lesion associated with any of the following:~Positive functional ischemia study~Ischemic symptoms and angiographic minimal lumen diameter stenosis ≥ 50% by core laboratory quantitative coronary angiography (QCA)~Revascularization of a target lesion with diameter stenosis ≥ 70% by core laboratory QCA without either ischemic symptoms or a positive functional study." (NCT00856856)
Timeframe: 2 years
| Intervention | percentage of participants (Number) |
|---|---|
| Absorb BVS | 6.0 |
"ID-TLR is defined as the revascularization at the target lesion associated with any of the following:~Positive functional ischemia study~Ischemic symptoms and angiographic minimal lumen diameter stenosis ≥ 50% by core laboratory quantitative coronary angiography (QCA)~Revascularization of a target lesion with diameter stenosis ≥ 70% by core laboratory QCA without either ischemic symptoms or a positive functional study." (NCT00856856)
Timeframe: 270 days
| Intervention | Percentage of participants (Number) |
|---|---|
| Absorb BVS | 2.0 |
"ID-TLR is defined as the revascularization at the target lesion associated with any of the following:~Positive functional ischemia study~Ischemic symptoms and angiographic minimal lumen diameter stenosis ≥ 50% by core laboratory quantitative coronary angiography (QCA)~Revascularization of a target lesion with diameter stenosis ≥ 70% by core laboratory QCA without either ischemic symptoms or a positive functional study." (NCT00856856)
Timeframe: 3 years
| Intervention | percentage of participants (Number) |
|---|---|
| Absorb BVS | 7.0 |
"ID-TLR is defined as the revascularization at the target lesion associated with any of the following:~Positive functional ischemia study~Ischemic symptoms and angiographic minimal lumen diameter stenosis ≥ 50% by core laboratory quantitative coronary angiography (QCA)~Revascularization of a target lesion with diameter stenosis ≥ 70% by core laboratory QCA without either ischemic symptoms or a positive functional study." (NCT00856856)
Timeframe: 30 days
| Intervention | percentage of participants (Number) |
|---|---|
| Absorb BVS | 0 |
"ID-TLR is defined as the revascularization at the target lesion associated with any of the following:~Positive functional ischemia study~Ischemic symptoms and angiographic minimal lumen diameter stenosis ≥ 50% by core laboratory quantitative coronary angiography (QCA)~Revascularization of a target lesion with diameter stenosis ≥ 70% by core laboratory QCA without either ischemic symptoms or a positive functional study." (NCT00856856)
Timeframe: 4 years
| Intervention | percentage of participants (Number) |
|---|---|
| Absorb BVS | 7.1 |
"ID-TLR is defined as the revascularization at the target lesion associated with any of the following:~Positive functional ischemia study~Ischemic symptoms and angiographic minimal lumen diameter stenosis ≥ 50% by core laboratory quantitative coronary angiography (QCA)~Revascularization of a target lesion with diameter stenosis ≥ 70% by core laboratory QCA without either ischemic symptoms or a positive functional study." (NCT00856856)
Timeframe: 5 years
| Intervention | percentage of participants (Number) |
|---|---|
| Absorb BVS | 8.0 |
"ID-TVR is the revascularization in the target vessel associated with any of the following:~Positive functional ischemia study~Ischemic symptoms and an angiographic minimal lumen diameter stenosis ≥ 50% by core laboratory quantitative coronary angiography (QCA)~Revascularization of a target vessel with diameter stenosis ≥ 70% by core laboratory QCA without either ischemic symptoms or a positive functional study." (NCT00856856)
Timeframe: 1 year
| Intervention | Percentage of participants (Number) |
|---|---|
| Absorb BVS | 4.0 |
"ID-TVR is the revascularization in the target vessel associated with any of the following:~Positive functional ischemia study~Ischemic symptoms and an angiographic minimal lumen diameter stenosis ≥ 50% by core laboratory quantitative coronary angiography (QCA)~Revascularization of a target vessel with diameter stenosis ≥ 70% by core laboratory QCA without either ischemic symptoms or a positive functional study." (NCT00856856)
Timeframe: 180 days
| Intervention | Percentage of participants (Number) |
|---|---|
| Absorb BVS | 2.0 |
"ID-TVR is the revascularization in the target vessel associated with any of the following:~Positive functional ischemia study~Ischemic symptoms and an angiographic minimal lumen diameter stenosis ≥ 50% by core laboratory quantitative coronary angiography (QCA)~Revascularization of a target vessel with diameter stenosis ≥ 70% by core laboratory QCA without either ischemic symptoms or a positive functional study." (NCT00856856)
Timeframe: 2 years
| Intervention | Percentage of participants (Number) |
|---|---|
| Absorb BVS | 8.0 |
"ID-TVR is the revascularization in the target vessel associated with any of the following:~Positive functional ischemia study~Ischemic symptoms and an angiographic minimal lumen diameter stenosis ≥ 50% by core laboratory quantitative coronary angiography (QCA)~Revascularization of a target vessel with diameter stenosis ≥ 70% by core laboratory QCA without either ischemic symptoms or a positive functional study." (NCT00856856)
Timeframe: 270 days
| Intervention | Percentage of participants (Number) |
|---|---|
| Absorb BVS | 2.0 |
"ID-TVR is the revascularization in the target vessel associated with any of the following:~Positive functional ischemia study~Ischemic symptoms and an angiographic minimal lumen diameter stenosis ≥ 50% by core laboratory quantitative coronary angiography (QCA)~Revascularization of a target vessel with diameter stenosis ≥ 70% by core laboratory QCA without either ischemic symptoms or a positive functional study." (NCT00856856)
Timeframe: 3 years
| Intervention | Percentage of participants (Number) |
|---|---|
| Absorb BVS | 10.0 |
"ID-TVR is the revascularization in the target vessel associated with any of the following:~Positive functional ischemia study~Ischemic symptoms and an angiographic minimal lumen diameter stenosis ≥ 50% by core laboratory quantitative coronary angiography (QCA)~Revascularization of a target vessel with diameter stenosis ≥ 70% by core laboratory QCA without either ischemic symptoms or a positive functional study." (NCT00856856)
Timeframe: 30 days
| Intervention | Percentage of participants (Number) |
|---|---|
| Absorb BVS | 0.0 |
"ID-TVR is the revascularization in the target vessel associated with any of the following:~Positive functional ischemia study~Ischemic symptoms and an angiographic minimal lumen diameter stenosis ≥ 50% by core laboratory quantitative coronary angiography (QCA)~Revascularization of a target vessel with diameter stenosis ≥ 70% by core laboratory QCA without either ischemic symptoms or a positive functional study." (NCT00856856)
Timeframe: 4 years
| Intervention | Percentage of participants (Number) |
|---|---|
| Absorb BVS | 10.0 |
"ID-TVR is the revascularization in the target vessel associated with any of the following:~Positive functional ischemia study~Ischemic symptoms and an angiographic minimal lumen diameter stenosis ≥ 50% by core laboratory quantitative coronary angiography (QCA)~Revascularization of a target vessel with diameter stenosis ≥ 70% by core laboratory QCA without either ischemic symptoms or a positive functional study." (NCT00856856)
Timeframe: 5 years
| Intervention | Percentage of participants (Number) |
|---|---|
| Absorb BVS | 11.0 |
"Late-Acquired Incomplete Apposition is defined as incomplete apposition of the scaffold at follow-up, which was not present post-procedure.~Incomplete Apposition: Failure of the scaffold to completely appose to the vessel wall after placement is defined as one or more scaffold strut separated from the vessel wall with evidence of blood speckles behind the strut in the ultrasound image." (NCT00856856)
Timeframe: 1 year
| Intervention | Percentage of participants (Number) |
|---|---|
| Absorb BVS | 3.6 |
"Late-Acquired Incomplete Apposition is defined as incomplete apposition of the scaffold at follow-up, which was not present post-procedure.~Incomplete Apposition: Failure of the scaffold to completely appose to the vessel wall after placement is defined as one or more scaffold strut separated from the vessel wall with evidence of blood speckles behind the strut in the ultrasound image." (NCT00856856)
Timeframe: 180 days
| Intervention | Percentage of participants (Number) |
|---|---|
| Absorb BVS | 7.5 |
"Late-Acquired Incomplete Apposition is defined as incomplete apposition of the scaffold at follow-up, which was not present post-procedure.~Incomplete Apposition: Failure of the scaffold to completely appose to the vessel wall after placement is defined as one or more scaffold strut separated from the vessel wall with evidence of blood speckles behind the strut in the ultrasound image." (NCT00856856)
Timeframe: 2 year
| Intervention | Percentage of participants (Number) |
|---|---|
| Absorb BVS | 2.6 |
"Late-Acquired Incomplete Apposition is defined as incomplete apposition of the scaffold at follow-up, which was not present post-procedure.~Incomplete Apposition: Failure of the scaffold to completely appose to the vessel wall after placement is defined as one or more scaffold strut separated from the vessel wall with evidence of blood speckles behind the strut in the ultrasound image." (NCT00856856)
Timeframe: 3 year
| Intervention | Percentage of participants (Number) |
|---|---|
| Absorb BVS | 7.0 |
(NCT00856856)
Timeframe: 1 year
| Intervention | mm^3 (Mean) |
|---|---|
| Absorb BVS | 106.33 |
(NCT00856856)
Timeframe: 2 years
| Intervention | mm^3 (Mean) |
|---|---|
| Absorb BVS | 107.66 |
(NCT00856856)
Timeframe: 3 years
| Intervention | mm^3 (Mean) |
|---|---|
| Absorb BVS | 103.31 |
(NCT00856856)
Timeframe: 5 years
| Intervention | mm^3 (Mean) |
|---|---|
| Absorb BVS | 106.36 |
(NCT00856856)
Timeframe: 1 year
| Intervention | mm^2 (Mean) |
|---|---|
| Absorb BVS | 5.90 |
(NCT00856856)
Timeframe: 2 years
| Intervention | mm^2 (Mean) |
|---|---|
| Absorb BVS | 6.00 |
(NCT00856856)
Timeframe: 3 years
| Intervention | mm^2 (Mean) |
|---|---|
| Absorb BVS | 6.06 |
(NCT00856856)
Timeframe: 5 years
| Intervention | mm^2 (Mean) |
|---|---|
| Absorb BVS | 6.21 |
(NCT00856856)
Timeframe: 1 year
| Intervention | mm^2 (Mean) |
|---|---|
| Absorb BVS | 5.92 |
(NCT00856856)
Timeframe: 2 years
| Intervention | mm^2 (Mean) |
|---|---|
| Absorb BVS | 6.00 |
(NCT00856856)
Timeframe: 3 years
| Intervention | mm^2 (Mean) |
|---|---|
| Absorb BVS | 6.06 |
(NCT00856856)
Timeframe: 5 years
| Intervention | mm^2 (Mean) |
|---|---|
| Absorb BVS | 6.22 |
(NCT00856856)
Timeframe: 1 year
| Intervention | mm (Mean) |
|---|---|
| Absorb BVS | 2.71 |
(NCT00856856)
Timeframe: 2 years
| Intervention | mm (Mean) |
|---|---|
| Absorb BVS | 2.72 |
(NCT00856856)
Timeframe: 3 years
| Intervention | mm (Mean) |
|---|---|
| Absorb BVS | 2.74 |
It is measured during QCA by the Angiographic Core Lab. (NCT00856856)
Timeframe: 5 years
| Intervention | mm (Mean) |
|---|---|
| Absorb BVS | 2.77 |
(NCT00856856)
Timeframe: 1 year
| Intervention | mm^2 (Mean) |
|---|---|
| Absorb BVS | 6.34 |
(NCT00856856)
Timeframe: 2 years
| Intervention | mm^2 (Mean) |
|---|---|
| Absorb BVS | 6.29 |
(NCT00856856)
Timeframe: 3 years
| Intervention | mm^2 (Mean) |
|---|---|
| Absorb BVS | 6.24 |
(NCT00856856)
Timeframe: 5 years
| Intervention | mm^2 (Mean) |
|---|---|
| Absorb BVS | 6.13 |
(NCT00856856)
Timeframe: 2 years
| Intervention | mm^2 (Mean) |
|---|---|
| Absorb BVS | 8.14 |
(NCT00856856)
Timeframe: 3 years
| Intervention | mm^2 (Mean) |
|---|---|
| Absorb BVS | 8.50 |
(NCT00856856)
Timeframe: 2 years
| Intervention | mm (Mean) |
|---|---|
| Absorb BVS | 3.19 |
(NCT00856856)
Timeframe: 3 years
| Intervention | mm (Mean) |
|---|---|
| Absorb BVS | 3.26 |
(NCT00856856)
Timeframe: 1 year
| Intervention | mm^2 (Mean) |
|---|---|
| Absorb BVS | 7.42 |
(NCT00856856)
Timeframe: 1 year
| Intervention | mm (Mean) |
|---|---|
| Absorb BVS | 3.06 |
(NCT00856856)
Timeframe: 1 year
| Intervention | mm^2 (Mean) |
|---|---|
| Absorb BVS | 0.17 |
(NCT00856856)
Timeframe: 2 years
| Intervention | mm^2 (Mean) |
|---|---|
| Absorb BVS | 0.15 |
(NCT00856856)
Timeframe: 3 years
| Intervention | mm^2 (Mean) |
|---|---|
| Absorb BVS | 0.19 |
(NCT00856856)
Timeframe: 1 year
| Intervention | mm^2 (Mean) |
|---|---|
| Absorb BVS | 4.28 |
(NCT00856856)
Timeframe: 2 years
| Intervention | mm^2 (Mean) |
|---|---|
| Absorb BVS | 4.29 |
(NCT00856856)
Timeframe: 3 years
| Intervention | mm^2 (Mean) |
|---|---|
| Absorb BVS | 4.45 |
(NCT00856856)
Timeframe: 5 years
| Intervention | mm^2 (Mean) |
|---|---|
| Absorb BVS | 4.15 |
(NCT00856856)
Timeframe: 1 year
| Intervention | mm^2 (Mean) |
|---|---|
| Absorb BVS | 4.29 |
(NCT00856856)
Timeframe: 2 years
| Intervention | mm^2 (Mean) |
|---|---|
| Absorb BVS | 4.29 |
(NCT00856856)
Timeframe: 3 years
| Intervention | mm^2 (Mean) |
|---|---|
| Absorb BVS | 4.45 |
(NCT00856856)
Timeframe: 5 years
| Intervention | mm^2 (Mean) |
|---|---|
| Absorb BVS | 4.15 |
The average of two orthogonal views (when possible) of the narrowest point within the area of assessment - in lesion, in scaffold or in segment. MLD is visually estimated during angiography by the Investigator; it is measured during QCA by the Angiographic Core Lab. (NCT00856856)
Timeframe: 2 years
| Intervention | mm (Mean) |
|---|---|
| Absorb BVS | 2.30 |
The average of two orthogonal views (when possible) of the narrowest point within the area of assessment - in lesion, in scaffold or in segment. MLD is visually estimated during angiography by the Investigator; it is measured during QCA by the Angiographic Core Lab. (NCT00856856)
Timeframe: 3 years
| Intervention | mm (Mean) |
|---|---|
| Absorb BVS | 2.34 |
The average of two orthogonal views (when possible) of the narrowest point within the area of assessment - in lesion, in scaffold or in segment. MLD is visually estimated during angiography by the Investigator; it is measured during QCA by the Angiographic Core Lab. (NCT00856856)
Timeframe: 5 years
| Intervention | mm (Mean) |
|---|---|
| Absorb BVS | 2.25 |
The average of two orthogonal views (when possible) of the narrowest point within the area of assessment - in lesion, in scaffold or in segment. MLD is visually estimated during angiography by the Investigator; it is measured during QCA by the Angiographic Core Lab. (NCT00856856)
Timeframe: 1 year
| Intervention | mm (Mean) |
|---|---|
| Absorb BVS | 2.30 |
(NCT00856856)
Timeframe: 2 year
| Intervention | mm^2 (Mean) |
|---|---|
| Absorb BVS | 6.33 |
(NCT00856856)
Timeframe: 3 years
| Intervention | mm^2 (Mean) |
|---|---|
| Absorb BVS | 6.66 |
(NCT00856856)
Timeframe: 2 years
| Intervention | mm (Mean) |
|---|---|
| Absorb BVS | 2.82 |
(NCT00856856)
Timeframe: 3 years
| Intervention | mm (Mean) |
|---|---|
| Absorb BVS | 2.89 |
(NCT00856856)
Timeframe: 1 year
| Intervention | mm^2 (Mean) |
|---|---|
| Absorb BVS | 5.96 |
(NCT00856856)
Timeframe: 1 year
| Intervention | mm (Mean) |
|---|---|
| Absorb BVS | 2.74 |
"Myocardial Infarction (MI):~Q wave MI: Development of new, pathological Q wave on the ECG.~Non-Q wave MI: Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves." (NCT00856856)
Timeframe: 1 year
| Intervention | percentage of participants (Number) |
|---|---|
| ABSORB Stent | 3.0 |
"Myocardial Infarction (MI):~Q wave MI: Development of new, pathological Q wave on the ECG.~Non-Q wave MI: Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves." (NCT00856856)
Timeframe: 2 years
| Intervention | percentage of participants (Number) |
|---|---|
| ABSORB Stent | 3.0 |
"Myocardial Infarction (MI):~Q wave MI: Development of new, pathological Q wave on the ECG.~Non-Q wave MI: Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves." (NCT00856856)
Timeframe: 3 years
| Intervention | percentage of participants (Number) |
|---|---|
| ABSORB Stent | 3.0 |
"Myocardial Infarction (MI):~Q wave MI: Development of new, pathological Q wave on the ECG.~Non-Q wave MI: Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves." (NCT00856856)
Timeframe: 4 years
| Intervention | percentage of participants (Number) |
|---|---|
| ABSORB Stent | 3.0 |
"Myocardial Infarction (MI):~Q wave MI: Development of new, pathological Q wave on the ECG.~Non-Q wave MI: Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves." (NCT00856856)
Timeframe: 5 years
| Intervention | percentage of participants (Number) |
|---|---|
| ABSORB Stent | 3.0 |
"Myocardial Infarction (MI):~Q wave MI: Development of new, pathological Q wave on the ECG.~Non-Q wave MI: Elevation of Creatine kinase (CK) levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves." (NCT00856856)
Timeframe: 30 days
| Intervention | percentage of participants (Number) |
|---|---|
| ABSORB Stent | 2.0 |
(NCT00856856)
Timeframe: 1 year
| Intervention | Number of struts (Mean) |
|---|---|
| Absorb BVS | 0.1 |
(NCT00856856)
Timeframe: 2 years
| Intervention | Number of struts (Mean) |
|---|---|
| Absorb BVS | 0.2 |
(NCT00856856)
Timeframe: 3 years
| Intervention | Number of struts (Mean) |
|---|---|
| Absorb BVS | 0.2 |
(NCT00856856)
Timeframe: 5 years
| Intervention | Number of struts (Mean) |
|---|---|
| Absorb BVS | 0.0 |
(NCT00856856)
Timeframe: 1 year
| Intervention | Number of Struts (Mean) |
|---|---|
| Absorb BVS | 162.1 |
(NCT00856856)
Timeframe: 2 years
| Intervention | Number of Struts (Mean) |
|---|---|
| Absorb BVS | 160.9 |
(NCT00856856)
Timeframe: 3 years
| Intervention | Number of Struts (Mean) |
|---|---|
| Absorb BVS | 145.2 |
(NCT00856856)
Timeframe: 5 years
| Intervention | Number of Struts (Mean) |
|---|---|
| Absorb BVS | 7.1 |
(NCT00856856)
Timeframe: 1 year
| Intervention | Percentage of Lumen Area Stenosis (Mean) |
|---|---|
| Absorb BVS | 28.70 |
(NCT00856856)
Timeframe: 2 years
| Intervention | Percentage of Lumen Area Stenosis (Mean) |
|---|---|
| Absorb BVS | 28.75 |
(NCT00856856)
Timeframe: 3 years
| Intervention | Percentage of Lumen Area Stenosis (Mean) |
|---|---|
| Absorb BVS | 28.01 |
(NCT00856856)
Timeframe: 5 years
| Intervention | Percentage of Lumen Area Stenosis (Mean) |
|---|---|
| Absorb BVS | 34.32 |
Dissection at follow-up that was present post-procedure. (NCT00856856)
Timeframe: 1 year
| Intervention | Percentage of participants (Number) |
|---|---|
| Absorb BVS | 0.0 |
Dissection at follow-up that was present post-procedure. (NCT00856856)
Timeframe: 180 days
| Intervention | Percentage of participants (Number) |
|---|---|
| Absorb BVS | 0.0 |
Dissection at follow-up that was present post-procedure. (NCT00856856)
Timeframe: 2 years
| Intervention | Percentage of participants (Number) |
|---|---|
| Absorb BVS | 0.0 |
Dissection at follow-up that was present post-procedure. (NCT00856856)
Timeframe: 3 years
| Intervention | Percentage of participants (Number) |
|---|---|
| Absorb BVS | 0.0 |
Dissection at follow-up that was present post-procedure. (NCT00856856)
Timeframe: 5 years
| Intervention | Percentage of participants (Number) |
|---|---|
| Absorb BVS | 0.0 |
"Persisting incomplete apposition is defined as incomplete apposition at follow-up that was present post-procedure.~Incomplete Apposition: Failure of the scaffold to completely appose to the vessel wall after placement is defined as one or more scaffold strut separated from the vessel wall with evidence of blood speckles behind the strut in the ultrasound image." (NCT00856856)
Timeframe: 1 year
| Intervention | Percentage of participants (Number) |
|---|---|
| Absorb BVS | 3.5 |
"Persisting incomplete apposition is defined as incomplete apposition at follow-up that was present post-procedure.~Incomplete Apposition: Failure of the scaffold to completely appose to the vessel wall after placement is defined as one or more scaffold strut separated from the vessel wall with evidence of blood speckles behind the strut in the ultrasound image." (NCT00856856)
Timeframe: 180 days
| Intervention | Percentage of participants (Number) |
|---|---|
| Absorb BVS | 2.3 |
"Persisting incomplete apposition is defined as incomplete apposition at follow-up that was present post-procedure.~Incomplete Apposition: Failure of the scaffold to completely appose to the vessel wall after placement is defined as one or more scaffold strut separated from the vessel wall with evidence of blood speckles behind the strut in the ultrasound image." (NCT00856856)
Timeframe: 2 year
| Intervention | Percentage of participants (Number) |
|---|---|
| Absorb BVS | 0.0 |
"Persisting incomplete apposition is defined as incomplete apposition at follow-up that was present post-procedure.~Incomplete Apposition: Failure of the scaffold to completely appose to the vessel wall after placement is defined as one or more scaffold strut separated from the vessel wall with evidence of blood speckles behind the strut in the ultrasound image." (NCT00856856)
Timeframe: 3 year
| Intervention | Percentage of participants (Number) |
|---|---|
| Absorb BVS | 0.0 |
Proximal Late Loss: proximal MLD post-procedure - proximal MLD at follow-up (proximal defined as within 5 mm of healthy tissue proximal to scaffold placement). (NCT00856856)
Timeframe: 1 year
| Intervention | Millimeter (Mean) |
|---|---|
| Absorb BVS | 0.12 |
Proximal Late Loss: proximal MLD post-procedure - proximal MLD at follow-up (proximal defined as within 5 mm of healthy tissue proximal to scaffold placement). (NCT00856856)
Timeframe: 180 days
| Intervention | Millimeter (Mean) |
|---|---|
| Absorb BVS | 0.07 |
Proximal Late Loss: proximal MLD post-procedure - proximal MLD at follow-up (proximal defined as within 5 mm of healthy tissue proximal to scaffold placement). (NCT00856856)
Timeframe: 2 years
| Intervention | Millimeter (Mean) |
|---|---|
| Absorb BVS | 0.12 |
Proximal Late Loss: proximal MLD post-procedure - proximal MLD at follow-up (proximal defined as within 5 mm of healthy tissue proximal to scaffold placement). (NCT00856856)
Timeframe: 3 years
| Intervention | Millimeter (Mean) |
|---|---|
| Absorb BVS | 0.14 |
Proximal Late Loss: proximal MLD post-procedure - proximal MLD at follow-up (proximal defined as within 5 mm of healthy tissue proximal to scaffold placement). (NCT00856856)
Timeframe: 5 years
| Intervention | Millimeter (Mean) |
|---|---|
| Absorb BVS | 0.14 |
"Scaffold thrombosis will be categorized as acute (≤ 1day), subacute (>1day ≤ 30 days) and late (>30 days) and will be defined as any of the following:~Clinical presentation of acute coronary syndrome with angiographic evidence of scaffold thrombosis (angiographic appearance of thrombus within or adjacent to a previously treated target lesion)~In the absence of angiography, any unexplained death, or acute MI (ST segment elevation or new Q-wave)* in the distribution of the target lesion within 30 days *(Non-specific ST /T changes and cardiac enzyme elevations do not suffice)~Any thromboses that occur less than 30 days after the index procedure will not be counted as restenosis." (NCT00856856)
Timeframe: 1 year
| Intervention | percentage of participants (Number) |
|---|---|
| Absorb BVS | 0 |
"Scaffold thrombosis will be categorized as acute (≤ 1day), subacute (>1day ≤ 30 days) and late (>30 days) and will be defined as any of the following:~Clinical presentation of acute coronary syndrome with angiographic evidence of scaffold thrombosis (angiographic appearance of thrombus within or adjacent to a previously treated target lesion)~In the absence of angiography, any unexplained death, or acute MI (ST segment elevation or new Q-wave)* in the distribution of the target lesion within 30 days *(Non-specific ST /T changes and cardiac enzyme elevations do not suffice)~Any thromboses that occur less than 30 days after the index procedure will not be counted as restenosis." (NCT00856856)
Timeframe: 2 years
| Intervention | percentage of participants (Number) |
|---|---|
| Absorb BVS | 0 |
"Scaffold thrombosis will be categorized as acute (≤ 1day), subacute (>1day ≤ 30 days) and late (>30 days) and will be defined as any of the following:~Clinical presentation of acute coronary syndrome with angiographic evidence of scaffold thrombosis (angiographic appearance of thrombus within or adjacent to a previously treated target lesion)~In the absence of angiography, any unexplained death, or acute MI (ST segment elevation or new Q-wave)* in the distribution of the target lesion within 30 days *(Non-specific ST /T changes and cardiac enzyme elevations do not suffice)~Any thromboses that occur less than 30 days after the index procedure will not be counted as restenosis." (NCT00856856)
Timeframe: 3 years
| Intervention | percentage of participants (Number) |
|---|---|
| Absorb BVS | 0 |
"Scaffold thrombosis will be categorized as acute (≤ 1day), subacute (>1day ≤ 30 days) and late (>30 days) and will be defined as any of the following:~Clinical presentation of acute coronary syndrome with angiographic evidence of scaffold thrombosis (angiographic appearance of thrombus within or adjacent to a previously treated target lesion)~In the absence of angiography, any unexplained death, or acute MI (ST segment elevation or new Q-wave)* in the distribution of the target lesion within 30 days *(Non-specific ST /T changes and cardiac enzyme elevations do not suffice)~Any thromboses that occur less than 30 days after the index procedure will not be counted as restenosis." (NCT00856856)
Timeframe: 30 days
| Intervention | percentage of participants (Number) |
|---|---|
| ABSORB Stent | 0 |
"Scaffold thrombosis will be categorized as acute (≤ 1day), subacute (>1day ≤ 30 days) and late (>30 days) and will be defined as any of the following:~Clinical presentation of acute coronary syndrome with angiographic evidence of scaffold thrombosis (angiographic appearance of thrombus within or adjacent to a previously treated target lesion)~In the absence of angiography, any unexplained death, or acute MI (ST segment elevation or new Q-wave)* in the distribution of the target lesion within 30 days *(Non-specific ST /T changes and cardiac enzyme elevations do not suffice)~Any thromboses that occur less than 30 days after the index procedure will not be counted as restenosis." (NCT00856856)
Timeframe: 4 years
| Intervention | percentage of participants (Number) |
|---|---|
| Absorb BVS | 0 |
"Scaffold thrombosis will be categorized as acute (≤ 1day), subacute (>1day ≤ 30 days) and late (>30 days) and will be defined as any of the following:~Clinical presentation of acute coronary syndrome with angiographic evidence of scaffold thrombosis (angiographic appearance of thrombus within or adjacent to a previously treated target lesion)~In the absence of angiography, any unexplained death, or acute MI (ST segment elevation or new Q-wave)* in the distribution of the target lesion within 30 days *(Non-specific ST /T changes and cardiac enzyme elevations do not suffice)~Any thromboses that occur less than 30 days after the index procedure will not be counted as restenosis." (NCT00856856)
Timeframe: 5 years
| Intervention | percentage of participants (Number) |
|---|---|
| Absorb BVS | 0 |
(NCT00856856)
Timeframe: 2 years
| Intervention | mm^3 (Mean) |
|---|---|
| Absorb BVS | 145.78 |
(NCT00856856)
Timeframe: 3 years
| Intervention | mm^3 (Mean) |
|---|---|
| Absorb BVS | 145.07 |
(NCT00856856)
Timeframe: 1 year
| Intervention | mm^3 (Mean) |
|---|---|
| Absorb BVS | 132.90 |
(NCT00856856)
Timeframe: 1 year
| Intervention | mm^3 (Mean) |
|---|---|
| Absorb BVS | 3.02 |
(NCT00856856)
Timeframe: 2 years
| Intervention | mm^3 (Mean) |
|---|---|
| Absorb BVS | 2.61 |
(NCT00856856)
Timeframe: 3 years
| Intervention | mm^3 (Mean) |
|---|---|
| Absorb BVS | 3.28 |
(NCT00856856)
Timeframe: 1 year
| Intervention | Percentage of participants (Number) |
|---|---|
| Absorb BVS | 0.0 |
(NCT00856856)
Timeframe: 180 days
| Intervention | Percentage of participants (Number) |
|---|---|
| Absorb BVS | 0.0 |
(NCT00856856)
Timeframe: 2 years
| Intervention | Percentage of participants (Number) |
|---|---|
| Absorb BVS | 2.6 |
(NCT00856856)
Timeframe: 3 years
| Intervention | Percentage of participants (Number) |
|---|---|
| Absorb BVS | 2.08 |
(NCT00856856)
Timeframe: 5 years
| Intervention | Percentage of participants (Number) |
|---|---|
| Absorb BVS | 0.0 |
(NCT00856856)
Timeframe: 1 year
| Intervention | mm^2 (Mean) |
|---|---|
| Absorb BVS | 1.38 |
(NCT00856856)
Timeframe: 2 years
| Intervention | mm^2 (Mean) |
|---|---|
| Absorb BVS | 1.99 |
(NCT00856856)
Timeframe: 3 years
| Intervention | mm^2 (Mean) |
|---|---|
| Absorb BVS | 2.25 |
(NCT00856856)
Timeframe: 1 year
| Intervention | mm^2 (Mean) |
|---|---|
| Absorb BVS | 1.54 |
(NCT00856856)
Timeframe: 2 years
| Intervention | mm^2 (Mean) |
|---|---|
| Absorb BVS | 2.13 |
(NCT00856856)
Timeframe: 3 years
| Intervention | mm^2 (Mean) |
|---|---|
| Absorb BVS | 2.44 |
(NCT00856856)
Timeframe: 1 year
| Intervention | Percent of Tissue Coverage Obstruction (Mean) |
|---|---|
| Absorb BVS | 19.40 |
(NCT00856856)
Timeframe: 2 years
| Intervention | Percent of Tissue Coverage Obstruction (Mean) |
|---|---|
| Absorb BVS | 25.22 |
(NCT00856856)
Timeframe: 3 years
| Intervention | Percent of Tissue Coverage Obstruction (Mean) |
|---|---|
| Absorb BVS | 27.01 |
(NCT00856856)
Timeframe: 1 year
| Intervention | Percent of Tissue Coverage Obstruction (Mean) |
|---|---|
| Absorb BVS | 21.61 |
(NCT00856856)
Timeframe: 2 years
| Intervention | Percent of Tissue Coverage Obstruction (Mean) |
|---|---|
| Absorb BVS | 27.10 |
(NCT00856856)
Timeframe: 3 years
| Intervention | Percent of Tissue Coverage Obstruction (Mean) |
|---|---|
| Absorb BVS | 29.36 |
(NCT00856856)
Timeframe: 1 year
| Intervention | mm^3 (Mean) |
|---|---|
| Absorb BVS | 24.40 |
(NCT00856856)
Timeframe: 2 years
| Intervention | mm^3 (Mean) |
|---|---|
| Absorb BVS | 35.51 |
(NCT00856856)
Timeframe: 3 years
| Intervention | mm^3 (Mean) |
|---|---|
| Absorb BVS | 38.47 |
(NCT00856856)
Timeframe: 1 year
| Intervention | mm^3 (Mean) |
|---|---|
| Absorb BVS | 27.27 |
(NCT00856856)
Timeframe: 2 years
| Intervention | mm^3 (Mean) |
|---|---|
| Absorb BVS | 38.12 |
(NCT00856856)
Timeframe: 3 years
| Intervention | mm^3 (Mean) |
|---|---|
| Absorb BVS | 41.76 |
Defined as scaffold intimal hyperplasia and calculated as 100*(Scaffold Volume - Lumen Volume)/Scaffold Volume by IVUS. (NCT00856856)
Timeframe: 1 year
| Intervention | percent of scaffold volume (Mean) |
|---|---|
| Absorb BVS | 1.47 |
Defined as scaffold intimal hyperplasia and calculated as 100*(Scaffold Volume - Lumen Volume)/Scaffold Volume by IVUS. (NCT00856856)
Timeframe: 180 days
| Intervention | percent of scaffold volume (Mean) |
|---|---|
| Absorb BVS | 1.22 |
Defined as scaffold intimal hyperplasia and calculated as 100*(Scaffold Volume - Lumen Volume)/Scaffold Volume by IVUS. (NCT00856856)
Timeframe: 2 year
| Intervention | percent of scaffold volume (Mean) |
|---|---|
| Absorb BVS | 3.33 |
Defined as scaffold intimal hyperplasia and calculated as 100*(Scaffold Volume - Lumen Volume)/Scaffold Volume by IVUS. (NCT00856856)
Timeframe: 3 year
| Intervention | percent of scaffold volume (Mean) |
|---|---|
| Absorb BVS | 4.19 |
Vasomotion function was assessed in reaction to nitrate administration. (NCT00856856)
Timeframe: 5 years
| Intervention | Millimeter (Mean) | |
|---|---|---|
| Pre-Nitro | Post-Nitro | |
| Absorb BVS | 2.49 | 2.56 |
7 reviews available for lactic acid and Arteriosclerosis, Coronary
| Article | Year |
|---|---|
Exercise Testing.
Topics: Athletes; Athletic Performance; Coronary Artery Disease; Exercise Test; Heart Diseases; Humans; Lact | 2019 |
Optical coherence tomography in bioabsorbable stents: mechanism of vascular response and guidance of stent implantation.
Topics: Absorbable Implants; Coronary Artery Disease; Humans; Lactic Acid; Percutaneous Coronary Interventio | 2014 |
Biodegradable polymer drug-eluting stents versus second-generation drug-eluting stents for patients with coronary artery disease: an update meta-analysis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Coated Materials, Biocompatible; Coronary Artery Disease | 2014 |
Current status of bioresorbable scaffolds in the treatment of coronary artery disease.
Topics: Absorbable Implants; Acute Coronary Syndrome; Coronary Angiography; Coronary Artery Disease; Humans; | 2014 |
ASIC3: a lactic acid sensor for cardiac pain.
Topics: Acid Sensing Ion Channels; Angina Pectoris; Animals; Coronary Artery Disease; Heart; Humans; Lactic | 2001 |
BioMatrix Biolimus A9-eluting coronary stent: a next-generation drug-eluting stent for coronary artery disease.
Topics: Animals; Coated Materials, Biocompatible; Coronary Artery Disease; Coronary Restenosis; Drug Carrier | 2006 |
Intravascular bioresorbable polymeric stents: a potential alternative to current drug eluting metal stents.
Topics: Absorbable Implants; Animals; Coronary Artery Disease; Drug-Eluting Stents; Humans; Lactic Acid; Pol | 2007 |
14 trials available for lactic acid and Arteriosclerosis, Coronary
| Article | Year |
|---|---|
A next-generation bioresorbable coronary scaffold system: from bench to first clinical evaluation: 6- and 12-month clinical and multimodality imaging results.
Topics: Absorbable Implants; Aged; Aged, 80 and over; Belgium; Cardiovascular Agents; Coronary Angiography; | 2014 |
Systemic metabolic markers and myocardial glucose uptake in type 2 diabetic and coronary artery disease patients treated for 16 weeks with rosiglitazone, a PPARγ agonist.
Topics: Aged; Blood Glucose; Coronary Artery Disease; Diabetes Mellitus, Type 2; Double-Blind Method; Female | 2014 |
Hemodynamic, Autonomic, Ventilatory, and Metabolic Alterations After Resistance Training in Patients With Coronary Artery Disease: A Randomized Controlled Trial.
Topics: Cardiac Output; Coronary Artery Disease; Exercise Therapy; Heart Rate; Hemodynamics; Humans; Lactic | 2017 |
Quantitative multi-modality imaging analysis of a bioabsorbable poly-L-lactic acid stent design in the acute phase: a comparison between 2- and 3D-QCA, QCU and QMSCT-CA.
Topics: Acute Disease; Aged; Angioplasty, Balloon, Coronary; Coated Materials, Biocompatible; Coronary Angio | 2008 |
Novel drug eluting stent system for customised treatment of coronary lesions: CUSTOM I feasibility trial 24 month results.
Topics: Aged; Angioplasty, Balloon, Coronary; Coated Materials, Biocompatible; Coronary Artery Disease; Drug | 2008 |
Monitoring in vivo absorption of a drug-eluting bioabsorbable stent with intravascular ultrasound-derived parameters a feasibility study.
Topics: Absorbable Implants; Angioplasty, Balloon, Coronary; Cardiovascular Agents; Coronary Artery Disease; | 2010 |
Association of lower habitual physical activity level with mitochondrial and endothelial dysfunction in patients with stable coronary artery disease.
Topics: Aged; Blood Glucose; Coronary Artery Disease; Endothelium, Vascular; Female; Humans; Lactic Acid; Li | 2012 |
Eccentric exercise in coronary patients: central hemodynamic and metabolic responses.
Topics: Adult; Aged; Coronary Artery Disease; Exercise Therapy; Female; Heart Rate; Hemodynamics; Humans; La | 2003 |
Metabolic and hemodynamic effects of high-dose insulin treatment in aortic valve and coronary surgery.
Topics: Aged; Aortic Valve Stenosis; Biomarkers; Blood Glucose; Coronary Artery Bypass; Coronary Artery Dise | 2005 |
The supportive value of pre-bypass L-glutamate loading in patients undergoing coronary artery bypass grafting.
Topics: Adenosine Triphosphate; Aged; Cardiopulmonary Bypass; Coronary Artery Bypass; Coronary Artery Diseas | 2005 |
Does poor oxygenation during one-lung ventilation impair aerobic myocardial metabolism in patients with symptomatic coronary artery disease?
Topics: Aged; Anaerobic Threshold; Cardiopulmonary Bypass; Coronary Artery Bypass; Coronary Artery Disease; | 2007 |
Contributions of myocardial ischemia and heart rate to ST segment changes in patients with or without coronary artery disease.
Topics: Adult; Aged; Arrhythmias, Cardiac; Blood Pressure; Cardiac Pacing, Artificial; Coronary Artery Disea | 2008 |
Spinal cord stimulation in severe angina pectoris.
Topics: Angina Pectoris; Coronary Artery Disease; Electric Stimulation Therapy; Humans; Lactic Acid; Myocard | 1995 |
Acute effects of heparin administration on the ischemic threshold of patients with coronary artery disease: evaluation of the protective role of the metabolic modulator trimetazidine.
Topics: Aged; Analysis of Variance; Anticoagulants; Biomarkers; Blood Pressure; Coronary Artery Disease; Dou | 2002 |
24 other studies available for lactic acid and Arteriosclerosis, Coronary
| Article | Year |
|---|---|
Oxygen delivery, oxygen consumption and decreased kidney function after cardiopulmonary bypass.
Topics: Acute Kidney Injury; Aged; Area Under Curve; Cardiopulmonary Bypass; Coronary Artery Disease; Female | 2019 |
High released lactate by epicardial fat from coronary artery disease patients is reduced by dapagliflozin treatment.
Topics: Adipose Tissue; Benzhydryl Compounds; Coronary Artery Disease; Glucose; Glucosides; Humans; Lactic A | 2020 |
Comment on: "High released lactate by epicardial fat from coronary artery disease patients is reduced by dapagliflozin treatment".
Topics: Benzhydryl Compounds; Coronary Artery Disease; Glucosides; Humans; Lactic Acid | 2020 |
Periostin promotes arterial calcification through PPARγ-related glucose metabolism reprogramming.
Topics: Animals; Aorta, Thoracic; Apoptosis; Cell Adhesion Molecules; Computed Tomography Angiography; Coron | 2021 |
A mechanistic model for drug release from PLGA-based drug eluting stent: A computational study.
Topics: Computer Simulation; Coronary Artery Disease; Coronary Stenosis; Coronary Vessels; Drug-Eluting Sten | 2017 |
Investigation of the long-term patency of a transmural heparinized polycaprolactone and poly(D,L-lactic/glycolic acid) scaffold.
Topics: Absorbable Implants; Animals; Anticoagulants; Biocompatible Materials; Coronary Artery Disease; Cycl | 2014 |
Decade of histological follow-up for a fully biodegradable poly-L-lactic acid coronary stent (Igaki-Tamai stent) in humans: are bioresorbable scaffolds the answer?
Topics: Absorbable Implants; Aged, 80 and over; Autopsy; Coronary Artery Disease; Coronary Vessels; Humans; | 2014 |
Novel biodegradable drug-eluting stent composed of poly-L-lactic acid and amorphous calcium phosphate nanoparticles demonstrates improved structural and functional performance for coronary artery disease.
Topics: Animals; Biocompatible Materials; Calcium Phosphates; Calorimetry, Differential Scanning; Coronary A | 2014 |
ABSORB biodegradable stents versus second-generation metal stents: a comparison study of 100 complex lesions treated under OCT guidance.
Topics: Absorbable Implants; Aged; Angioplasty, Balloon, Coronary; Case-Control Studies; Coronary Angiograph | 2014 |
Magnetic resonance imaging of bioresorbable vascular scaffolds: potential approach for noninvasive evaluation of coronary patency.
Topics: Acute Coronary Syndrome; Aged; Biocompatible Materials; Blood Vessel Prosthesis Implantation; Corona | 2015 |
Sex differences in the impact of CYP2C19 polymorphisms and low-grade inflammation on coronary microvascular disorder.
Topics: Aged; Biomarkers; C-Reactive Protein; Case-Control Studies; Chi-Square Distribution; Coronary Artery | 2016 |
Three-month evaluation of strut healing using a novel optical coherence tomography analytical method following bioresorbable polymer everolimus-eluting stent implantation in humans: the TIMELESS study.
Topics: Absorbable Implants; Acute Coronary Syndrome; Aged; Cardiovascular Agents; Chromium; Coronary Angiog | 2017 |
Late stent recoil of the bioabsorbable everolimus-eluting coronary stent and its relationship with plaque morphology.
Topics: Aged; Biocompatible Materials; Coronary Artery Disease; Coronary Vessels; Drug-Eluting Stents; Evero | 2008 |
Metabolomic profiling reveals distinct patterns of myocardial substrate use in humans with coronary artery disease or left ventricular dysfunction during surgical ischemia/reperfusion.
Topics: Aged; Anaerobic Threshold; Cardiac Output; Cardiopulmonary Bypass; Carnitine; Coronary Artery Diseas | 2009 |
[Comparative characteristic of intracellular metabolism in neutrophils of healthy adolescents and adults without coronary heart disease].
Topics: Adolescent; Adult; Antioxidants; Catalase; Child; Coronary Artery Disease; Female; Glutathione Reduc | 2009 |
Mitochondrial dysfunction induced by statin contributes to endothelial dysfunction in patients with coronary artery disease.
Topics: Aged; Biomarkers; Brachial Artery; Coronary Artery Disease; Dose-Response Relationship, Drug; Endoth | 2010 |
Paclitaxel/sirolimus combination coated drug-eluting stent: in vitro and in vivo drug release studies.
Topics: Animals; Antineoplastic Agents; Aorta, Abdominal; Calcium Phosphates; Coronary Artery Disease; Coron | 2011 |
Long-Term (>10 Years) clinical outcomes of first-in-human biodegradable poly-l-lactic acid coronary stents: Igaki-Tamai stents.
Topics: Absorbable Implants; Aged; Biopsy; Cohort Studies; Coronary Angiography; Coronary Artery Disease; Co | 2012 |
The disappearing stent: when plastic replaces metal.
Topics: Absorbable Implants; Coronary Artery Disease; Female; Humans; Lactic Acid; Male; Myocardial Revascul | 2012 |
Differences in neointimal thickness between the adluminal and the abluminal sides of malapposed and side-branch struts in a polylactide bioresorbable scaffold: evidence in vivo about the abluminal healing process.
Topics: Absorbable Implants; Aged; Angioplasty, Balloon, Coronary; Australia; Cardiovascular Agents; Cell Pr | 2012 |
Comparison of in vivo acute stent recoil between the bioabsorbable everolimus-eluting coronary stent and the everolimus-eluting cobalt chromium coronary stent: insights from the ABSORB and SPIRIT trials.
Topics: Aged; Angioplasty, Balloon, Coronary; Biocompatible Materials; Biomechanical Phenomena; Cardiovascul | 2007 |
ICVTS on-line discussion A. Further testing is warranted to detect more subtle degrees...
Topics: Anaerobic Threshold; Animals; Cardiopulmonary Bypass; Coronary Artery Bypass; Coronary Artery Diseas | 2007 |
Polymeric stents: degradable but strong.
Topics: Angioplasty, Balloon, Coronary; Biocompatible Materials; Biomechanical Phenomena; Cardiovascular Age | 2007 |
Angina pectoris caused by coronary microvascular spasm.
Topics: Acetylcholine; Aged; Angina, Unstable; Coronary Angiography; Coronary Artery Disease; Coronary Circu | 1998 |